Indian gatifloxacin ban excludes ophthalmic products
This article was originally published in Scrip
Executive Summary
India has clarified that its ban on the antibacterial gatifloxacin does not apply to ophthalmic formulations, bringing relief to more than half a dozen manufacturers of these eyecare products, including Allergan, which markets a preparation as Zymar.